Lori Laffel, M.D., M.P.H., has been appointed to the newly formed Research Advisory Committee (RAC) of the JDRF, the leading global organization funding type 1 diabetes (T1D) research.
Joslin Diabetes Center, the, the world-renowned diabetes expert, has appointed John A. Perry, CFRE, a skilled fundraising professional with extensive experience in healthcare philanthropy, as Chief Development Officer effective February 1.
To ensure that this population receives proper care, the American Diabetes Association has issued its first position statement to address the management of diabetes in long-term care facilities, which include assisted living, skilled nursing and nursing facilities.
The Greater Boston Chamber of Commerce has awarded Lori Laffel, M.D., MPH, Chief of the Pediatric, Adolescent and Young Adult Section at Joslin Diabetes Center and Professor of Pediatrics at Harvard Medical School, the Achievement in the Professions distinction for the 2016 Pinnacle Awards.
The Wolf Foundation announced earlier this week that it has awarded the Wolf Prize in Medicine to C. Ronald Kahn, M.D., Chief Academic Officer and Senior Investigator at Joslin Diabetes Center and the Mary K. Iacocca Professor of Medicine at Harvard Medical School.
Now researchers at Joslin Diabetes Center have identified a key protein produced in the liver that aids in accelerating the growth of these cells.
A clinical trial among more than 300 patients has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy (PDR), a complication of diabetes that can severely damage eyesight.
The Harold Hamm Diabetes Center at the University of Oklahoma awarded C. Ronald Kahn, M.D., Chief Academic Officer and Senior Investigator at Joslin Diabetes Center and the Mary K. Iacocca Professor of Medicine at Harvard Medical School, the Harold Hamm International Prize for Biomedical Research in Diabetes in a ceremony in Oklahoma City, OK.
Dr. Peter Amenta has been named President and CEO of Joslin Diabetes Center. Joslin Diabetes Center has 300 scientists working toward a cure for diabetes and its complications. Each year more than 100 clinical trials and human subject studies are conducted at Joslin; and 21,000 adult and pediatric patients visit the Joslin Clinic for appointments. Joslin has received National Institute of Health (NIH) funding of $18M every year since 2012.
A follow-up study has shown that these peripheral lesions, which are not detected by traditional eye imaging, correlate very closely with the loss of retinal blood flow called retinal “non-perfusion” caused by loss of small blood vessels or capillaries.
Researchers at Joslin Diabetes Center found that one strain of mice which were genetically prone to become obese became resistant to excess weight gain after their populations of gut microbiota were transformed simply by an sharing an environment with other mice.
Investigators at the Joslin Diabetes Center now have shown that eyes with diabetic retinal lesions predominantly in peripheral areas of the retina that are seen in UWF images but not in traditional retinal photographs show surprisingly higher risks of progressing to advanced stages of vision-threatening diabetic retinopathy.
The Boston Business Journal (BBJ) has selected three recipients from Joslin Diabetes Center to receive the 2015 Healthcare Heroes Awards, which honors those who have worked tirelessly to improve the overall health and wellness of those living in Massachusetts and beyond.
Joslin scientists have advanced understanding of how the cellular repair process is impaired in type 1 diabetes, which can cause cell death and lead to complications.
A team of researchers led by Yu-Hua Tseng, Ph.D., Investigator in the Section on Integrative Physiology and Metabolism at Joslin Diabetes Center and an Associate Professor of Medicine at Harvard Medical School, has created cell lines of human brown and white fat precursor cells that will help investigators to pick apart the factors that drive the development and activity of each type of cell.
Joslin Diabetes Center announced today that San MediTech, located in Beijing, China, has joined the Joslin Institute for Technology Translation (JITT) as a Founding Member.
In a ceremony on May 15 in Dublin, Ireland, The Fondation IPSEN awarded C. Ronald Kahn, M.D., Chief Academic Officer and Senior Vice President at Joslin Diabetes Center and the Mary K. Iacocca Professor of Medicine at Harvard Medical School, the 2015 Endocrine Regulation Prize.
Research in the lab of Edward P. Feener, Ph.D., Investigator in the Section on Vascular Cell Biology and Director of the Proteomics Core at Joslin Diabetes Center and an Associate Professor of Medicine at Harvard Medical School, now has shown that a substantial percentage of patients with DME do not have high levels of VEGF in the fluid inside their eyes but do have high levels of a protein called PKal (plasma kallikrein) and associated molecules that are key players in an inflammatory molecular pathway involved in the disease.
Joslin researchers have uncovered the action of a gene that regulates the education of T cells, providing insight into how and why the immune system begins mistaking the body’s own tissues for targets.
Research led by Joslin Diabetes Center's Myra Lipes, MD, has identified one culprit in heart failure—an autoimmune reaction triggered by heart attacks. In a recent Current Diabetes Reports paper, Dr. Lipes and her colleague Alfonso Galderisi review progress in understanding the autoimmune mechanism and taking steps toward diagnosing and treating it.
Joslin Diabetes Center and Daegu-Gyeongbuk Free Economic Zone (DGFEZ) have signed a memorandum of understanding (MOU) formalizing their mutual strong commitment to navigate avenues for potential partnership.
Joslin Diabetes Center and Sunshine Insurance Group Corporation Limited have announced today that they are collaborating to design and develop a Diabetes Center of Excellence in Weifang, Shandong Province, China.
Joslin Diabetes Center announced today that they have entered into a partnership with Johnson and Johnson Medical (Shanghai) Co. Ltd (hereafter, JJMS) to improve glycemic control for people with diabetes who are hospitalized in Chinese hospitals.
People with diabetes are more prone to anxiety and depression than those with other chronic diseases that require similar levels of management.
In the first clinical trial directly comparing three drugs most commonly used to treat diabetic macular edema, researchers found all were effective in improving vision and preventing vision loss. However, one drug, aflibercept, provided greater improvement for people with more severe vision loss when treatment was initiated.
A pilot study led by researchers at Joslin Diabetes Center has revealed that it is possible to use magnetic resonance imaging (MRI) to "see" the inflammation in the pancreas that leads to type 1 diabetes.
Joslin Diabetes Center announced today that Insulet Corporation (NASDAQ: PODD), has joined the Joslin Institute for Technology Translation (JITT) as a Founding Member.
The American Diabetes Association announced today that they are lowering the Body Mass Index (BMI) cut point for which they recommend screening Asian Americans for type 2 diabetes.
In a study published today by Nature, researchers at Joslin Diabetes Center used a microscopic worm (C. elegans) to identify a new path that could lead to drugs to slow aging and the chronic diseases that often accompany it—and might even lead to better cosmetics.
Rohit Kulkarni, M.D., Ph.D., Senior Investigator in the Section on Islet Cell and Regenerative Biology at Joslin Diabetes Center and Associate Professor at Harvard Medical School, coauthored a paper that was published today in Diabetes, which voiced concerns about the increasing difficulty of access to high quality islet cells for diabetes research.
Mary R. Loeken, Ph.D., Investigator in the Section on Islet Cell and Regenerative Biology at Joslin Diabetes Center and Associate Professor of Medicine at Harvard Medical School, has discovered a molecular pathway responsible for neural tube defects in diabetic pregnancies.
Lori Laffel, M.D., M.P.H., Chief of Joslin’s clinical programs for Children, Adolescents and Young Adults, and Senior Investigator in the Section on Genetics and Epidemiology, has been promoted by Harvard Medical School to Professor of Pediatrics.
Why are Asian Americans at higher risk of developing type 2 diabetes than Caucasian Americans, and prone to develop the disease at lower body weights? One part of this puzzle may lie in the transition from traditional high-fiber, low-fat Asian diets to current westernized diets, which may pose extra risks for those of Asian heritage, says George King, M.D., Senior Vice President and Chief Scientific Officer at Joslin Diabetes Center and the senior author of the study.
George King, M.D., Chief Scientific Officer and Senior Vice President of Joslin Diabetes Center and Professor of Medicine at Harvard Medical School, and Lloyd Paul Aiello, M.D., Ph.D., Director of the Beetham Eye Institute (BEI) and Professor of Ophthalmology at Harvard Medical School, were among seven individuals including colleagues from Massachusetts Eye and Ear Infirmary, Genentech and UC San Diego to receive the 2014 Antonio Champalimaud Vision Award for their contributions toward the discovery of treatments inhibiting vascular endothelial growth factor (VEGF) for ocular diseases. Drs. King and Aiello performed pivotal work in this area regarding the retinal diseases of proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME).
In a comprehensive review of recent randomized clinical trials and observational studies of diabetes and nutrition, Joslin Diabetes Center and Harvard School of Public Health investigators have identified specific foods and dietary patterns that are beneficial in preventing and controlling diabetes.
– In a letter to United States Senators Susan Collins (R-Me) and Jeanne Shaheen (D-NH), John L. Brooks III, President and CEO of Joslin Diabetes Center, expressed Joslin’s strong support for legislation sponsored by the two senators that would extend Medicare coverage to include continuous glucose monitors (CGM).
Lori Laffel, M.D., MPH, Chief of the Pediatric, Adolescent and Young Adult Section at Joslin Diabetes Center and Associate Professor of Pediatrics at Harvard Medical School, oversees the largest pediatric diabetes clinic in New England has over 25 years of experience treating pediatric patients with diabetes.
Scientists at Joslin Diabetes Center now have created the first iPSCs that offer a human model of insulin resistance, a key driver of type 2 diabetes.
– Edward Horton, M.D., Senior Investigator at Joslin Diabetes Center and Professor of Medicine at Harvard Medical School, received the Master of the American College of Endocrinology (MACE) Award at the American Association of Clinical Endocrinologists (AACE) 23rd Annual Scientific & Clinical Congress in Las Vegas this past May.
When a pregnant mother is undernourished, her child is at a greater than average risk of developing obesity and type 2 diabetes, in part due to so-called ‘epigenetic’ effects.
Building upon their earlier research on the biology of fat metabolism, Joslin scientists discovered that microRNAs –small RNA molecules that play important roles in regulation in many types of tissue – play a major role in the distribution and determination of fat cells and whole body metabolism.
Joslin Diabetes Center and Carlos Slim Health Institute (CSHI) announced they have created a partnership to develop a series of online “virtual” case based interactive educational materials for primary care physicians in Mexico.
Joslin Diabetes Center and Steno Diabetes Center today announced a long-term partnership to improve clinical outcomes in diabetes care.
The results of a 20-year study confirm that people with Type 1 diabetes who have developed kidney complications can slow the progress of their complications by improving control of their blood glucose over the long term. This finding may lead to changes in clinical practice for this population.
Joslin Diabetes Center announced today that Lori Laffel, M.D., M.P.H., Chief of the Pediatric, Adolescent and Young Adult Section at Joslin and Associate Professor of Pediatrics at Harvard Medical School, and Howard Wolpert, M.D., Director of the Joslin Institute for Technology Translation (JITT) and Assistant Professor of Medicine at Harvard Medical School, will be honored as Research Champions at the JDRF’s upcoming Boston Gala.
Three researchers from Joslin Diabetes Center will be presented with awards at the American Diabetes Association’s (ADA) 74th Scientific Sessions.
Decades after being diagnosed with type 1 diabetes, some Joslin 50-Year Medalists, who have lived 50 or more years with the disease, maintain certain types of blood cells that could help to repair blood vessels.
Sunstar Inc., a Switzerland-based, leading company in oral health care and one of the first businesses to emphasize an integrated approach to the relationship between oral health and systemic disease, and Joslin Diabetes Center, the world's largest diabetes research and clinical care organization dedicated to the prevention, treatment and cure of diabetes, have renewed their commitment to the Joslin Sunstar Diabetes Education Initiative (JSDEI).
TVM Capital Healthcare Partners, the region’s first private equity firm dedicated exclusively to the healthcare sector, has signed an affiliation with Joslin Diabetes Center. Located in Boston, Massachusetts, Joslin is the world's leading diabetes research, clinical care and education organization dedicated to the prevention, treatment and cure of diabetes. Joslin is an independent, non-profit institution affiliated with Harvard Medical School.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right